Phase III trial of oral capsule formulation of Hep-114 in patients with toxic liver damage

Trial Profile

Phase III trial of oral capsule formulation of Hep-114 in patients with toxic liver damage

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Hep 114 (Primary)
  • Indications Liver injury
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 11 Feb 2016 Status changed from recruiting to completed, as per TGV-Laboratories media release.
    • 06 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top